Search clinical trials for: fluticasone/propionate salmeterol combination

Total 16121 results

GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
University of Colorado, Denver
United States Department of Defense

Recruiting

Advair HFA in Healthy and HAPE Predisposed Subjects (SWIFTARC)

Altitude Edema

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Novartis Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Imperial College London
European Research Council

Recruiting

Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma (MAELABA)

Asthma

United Kingdom
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Asthma

United States
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
Assistance Publique - Hôpitaux de Paris
GlaxoSmithKline

Terminated

Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (RESPPEDOBS)

Bronchiolitis Obliterans | Respiratory Disease | Stem Cell Transplant Complications

France
Elpen Pharmaceutical Co. Inc.

Completed

A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination (RETRIEVE)

COPD | COPD Exacerbation

Greece
Allergy & Asthma Medical Group & Research Center

Completed

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

Asthma | Candidiasis, Oral | Voice Disorders

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Brigham and Women's Hospital

Completed

Replication of the INSPIRE Trial in Healthcare Claims Data

Chronic Obstructive Pulmonary Disease

United States
Columbia University

Completed

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (ARGARG)

Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Elpen Pharmaceutical Co. Inc.

Completed

Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler

Asthma
Kindeva Drug Delivery

Completed

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Healthy

United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Inhalation Sciences Sweden AB
CTC Clinical Trial Consultants AB; Pharm-Analyt Labor GmbH; PlantVision AB

Completed

Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System

Nebulizers and Vaporizers

Sweden
Mylan Pharma UK Ltd.

Completed

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Asthma | COPD

United States
Mylan Pharma UK Ltd.

Completed

MGR001 / Advair Diskus Local Equivalence Study in Asthma

Asthma

United States
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
Organon and Co

Completed

Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)

Asthma
University Hospital, Bordeaux

Completed

Description of the Ability to Learn How to Handle Inhaler Devices in COPD (INTUITIVE)

Chronic Obstructive Pulmonary Disease (COPD)

France
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Non-invasive Measures of Distal Lung Disease in Asthmatics

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Asthma, Allergic

China
Novartis Pharmaceuticals

Completed

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (ARGON)

Asthma

Germany, India, Israel, Poland, Argentina, Russian Federation, Greece, Serbia, Turkey, Hungary, Mexico, Peru, Slovakia, Czechia, South Africa, Taiwan, Vietnam, Spain, Colombia, Chile
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Asthma

Germany, Netherlands, United Kingdom, China, Romania, Bulgaria
Actavis Inc.
Teva Pharmaceuticals USA

Completed

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Asthma

United States
Children's Hospital Medical Center, Cincinnati

Completed

Personalized Treatment Algorithms for Difficult-to-treat Asthma

Asthma in Children

United States
Wake Forest University Health Sciences

Terminated

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

COPD | COPD Exacerbation

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
NYU Langone Health
National Institute for Occupational Safety and Health (NIOSH/CDC)

Completed

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

Lung Diseases | Medication Compliance

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
University of Virginia
National Institutes of Health (NIH)

Completed

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs

Pulmonary Disease, Chronic Obstructive

Netherlands, United Kingdom
Cipla Ltd.

Completed

BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients

Bronchial Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI

Bronchial Asthma

Poland, Ukraine
University of Dundee
AstraZeneca; NHS Tayside

Completed

Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (MUSIC)

Chronic Obstructive Pulmonary Disease

United Kingdom
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade

Bioequivalence

Greece

3

Subscribe